A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621
Keyword(s):
Phase Ii
◽
2011 ◽
Vol 6
(6)
◽
pp. 1117-1120
◽